ER 30346 (ravuconazole)

09/01/2021 - "Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease."
07/01/2010 - "We conclude that ravuconazole has potent suppressive but not curative activity in the canine model of acute Chagas' disease, probably due to its unfavorable pharmacokinetic properties (half-life, 8.8 h). "
01/01/2003 - "In murine acute models of acute Chagas disease, it was found that ravuconazole treatment led to high levels of parasitological cures, but only when given twice a day (b.i.d.), consistent with its short terminal half-life in mice (4 h). "
01/01/2003 - "In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease."
07/01/2010 - "The longer half-life of ravuconazole in humans (4 to 8 days) makes it a promising drug for assessment for use as chemotherapy in human Chagas' disease."

02/01/2002 - "All three doses of ravuconazole improved survival and also reduced the tissue burden of ASPERGILLUS: In this model of invasive aspergillosis, ravuconazole showed significant activity and may be a useful compound in human disease."
02/01/2002 - "Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis."
10/01/1996 - "Of the drugs tested, ER-30346 was the most effective drug against systemic aspergillosis. "
12/01/2000 - "Ravuconazole eliminated mortality, cleared aspergillus antigen from the serum, and eliminated Aspergillus fumigatus organisms from tissues of both lethally and sublethally challenged immunosuppressed animals with invasive aspergillosis. "
01/01/2008 - "Isavuconazole and ravuconazole are extremely similar, with a broad spectrum of activity, a very long half-life and large volume of distribution and good in vivo data supporting their efficacy in invasive aspergillosis and candidosis. "

12/01/2000 - "Additional studies are needed to determine the potential of ravuconazole for use in the treatment of this infection."
10/01/1996 - "Further studies are needed to determine the potential of ER-30346 for use in the treatment of these infections."
12/01/2001 - "Fluconazole at 25 mg/kg cured no infection in any tissue, whereas 25 mg of ravuconazole/kg cleared infection in all tissues from 50% of mice. "
04/01/2003 - "We used a neutropenic murine model of disseminated Candida albicans infection to similarly characterize the time course activity of the new triazole ravuconazole. "
01/01/2020 - "In this study, we evaluated the effect of ravuconazole, an EBI, combined with amlodipine, a calcium channel blocker, upon Trypanosoma cruzi experimental infection. "

06/01/2021 - "Ravuconazole was in good active against C. auris and vaginal Candida isolates, which suggested ravuconazole could be used in the treatment of drug-resistant candidiasis."
06/01/2021 - "To investigate the activity of ravuconazole against C. auris and vaginal Candida isolates of China and assess the feasibility of ravuconazole in the treatment of candidiasis caused by C. auris and other Candida spp. We determined the in vitro activity of ravuconazole and 9 comparators against 15 C. auris isolates and determined the MIC of ravuconazole on 525 vaginal Candida isolates (Candida albicans, Candida tropicalis, Candida glabrata and Candida parapsilosis) from 9 provinces of China by Clinical and Laboratory Standards Institute (CLSI) methodology. "
07/01/2003 - "Ravuconazole has shown efficacy in candidiasis in immunocompromised patients, and onychomycosis in healthy patients. "
10/01/1996 - "ER-30346 was also effective against pulmonary candidiasis caused by fluconazole-resistant C. "
04/01/2003 - "In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model."

10/01/1996 - "Thus, ER-30346 shows efficacy in murine aspergillosis, candidiasis, and cryptococcosis models. "
10/01/1996 - "In experimental murine models of pulmonary aspergillosis, candidiasis, and cryptococcosis, ER-30346 reduced the numbers of CFU in the lungs significantly compared with the numbers of CFU in the lungs of the controls (P < 0.05). "
10/01/1996 - "In mice with intracranial cryptococcosis, ER-30346 reduced the numbers of CFU in the brains significantly compared with the numbers of CFU in the brains of the controls (P < 0.05) and was more effective than itraconazole and as effective as fluconazole. "
10/01/1996 - "Against pulmonary candidiasis and cryptococcosis, ER-30346 was more effective than itraconazole and was as effective as fluconazole. "
10/01/1996 - "Against systemic candidiasis and cryptococcosis, ER-30346 was comparable in efficacy to fluconazole and was more effective than itraconazole. "